Substituted Pyrazolo[1,5-a]pyrimidine-7-amine CDK Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK inhibitors, such as those targeting CDK12 and CDK13, often lack selectivity and potency, particularly in degrading Cyclin K, which is crucial for kinase activity, leading to off-target effects and reduced efficacy in treating proliferative disorders and cancers.
Innovation Solution
Development of substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds (PPA compounds) that selectively inhibit CDK12 and CDK13 while also acting as Cyclin K degraders, enhancing cellular potency and selectivity by promoting the degradation of Cyclin K, a key cofactor for these kinases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current CDK inhibitors are used to target CDK12 and CDK13, then kinase inhibition is achieved, but selectivity and potency are insufficient due to inability to degrade Cyclin K
Solution Approach 1:
The patent combines two functions into a single compound: CDK12/13 kinase inhibition and Cyclin K degradation. The PPA compounds simultaneously inhibit the kinase activity of CDK12/13 and promote proteasomal degradation of Cyclin K, the essential regulatory subunit required for CDK activation. This dual mechanism resolves the contradiction by achieving both high selectivity (through specific Cyclin K degradation) and high efficacy (through combined kinase inhibition and cofactor removal).
Solution Approach 2:
The invention changes the mechanism of action parameter from simple kinase inhibition to a dual mechanism involving both kinase inhibition and protein degradation. By introducing the degrader function that specifically targets Cyclin K for proteasomal degradation, the compound achieves prolonged cellular potency and enhanced selectivity, as Cyclin K has a long half-life and its degradation leads to sustained inhibition of CDK12/13 activity.
2Adaptability or versatility
If CDK inhibitors lack selectivity, then broader kinase coverage is achieved, but off-target effects increase reducing treatment efficacy
Solution Approach 1:
The patent extracts the essential regulatory component (Cyclin K) from the CDK complex and selectively targets it for degradation. By specifically degrading Cyclin K rather than inhibiting multiple CDK kinases broadly, the compound achieves high selectivity for CDK12/13 pathways while avoiding off-target effects on other CDKs. This extraction approach removes the source of both desired activity and potential off-target toxicity.
Data Source
AI summary
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds PPA that, inter alia, inhibit cyclin-dependent protein kinases (CDKs), especially CDK12 and/or CDK13, and are selective, for example, for CDK12 and/or CDK13 as compared to CDK7. In addition to selectively inhibiting CDK12 and/or CDK13, the compounds also act as selective Cyclin K degraders thereby removing the key cofactor required for CDK12 and/or CDK13 activation; this confers additional cellular potency and selectivity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK, especially CDK12 and/or CDK13; and to treat disorders including: disorders that are associated with CDK, especially CDK12 and/or CDK13; disorders that result from an inappropriate activity of a CDK, especially CDK12 and/or CDK13; disorders that are associated with CDK mutation, especially CDK12 and/or CDK13 mutation; disorders that are associated with CDK overexpression, especially CDK12 and/or CDK13 overexpression; disorders that are associated with upstream pathway activation of CDK, especially CDK12 and/or CDK13; disorders that are ameliorated by the inhibition of CDK, especially CDK12 and/or CDK13; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; cardiovascular disorders (including atherosclerosis); autoimmune disorders (including rheumatoid arthritis); and disorders caused by dysfunction of translation in cells (including muscular dystrophy). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., a DNA repair inhibitor, an immune checkpoint inhibitor, an agent stimulating the immune system, a cell cycle checkpoint inhibitor, a Her2 blocker, a transcriptional inhibitor, a cytotoxic chemotherapeutic agent, etc.